Free Trial
NYSE:DHR

Danaher Q3 2025 Earnings Report

Danaher logo
$185.72 +0.89 (+0.48%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Danaher EPS Results

Actual EPS
N/A
Consensus EPS
$1.72
Beat/Miss
N/A
One Year Ago EPS
N/A

Danaher Revenue Results

Actual Revenue
N/A
Expected Revenue
$6.00 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Danaher Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Tuesday, October 21, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Danaher? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Danaher and other key companies, straight to your email.

About Danaher

Danaher (NYSE:DHR) is a global science and technology innovator that designs, manufactures and markets professional instrumentation and industrial technological products. The company operates through three primary segments—Life Sciences, Diagnostics, and Environmental & Applied Solutions—offering a broad range of products that support research, healthcare delivery and environmental monitoring. Its Life Sciences segment provides reagents, consumables and instruments under brands such as Beckman Coulter and Leica Microsystems, while the Diagnostics segment offers molecular diagnostics, clinical chemistry and virology solutions under businesses including Cepheid and Beckman Coulter Diagnostics. The Environmental & Applied Solutions segment delivers water quality analyzers, fluid management systems and code-printing equipment through brands like Hach, Videojet and Pall Corporation.

Headquartered in Washington, D.C., Danaher was founded in 1969 and adopted its current name in the mid-1980s. Since its inception, the company has pursued disciplined growth through a combination of organic investment and strategic acquisitions, leveraging the Danaher Business System—a continuous improvement framework focused on lean manufacturing, customer-centric innovation and talent development. Over the years, Danaher has expanded its footprint to serve researchers, clinicians and industrial customers in more than 60 countries worldwide.

Danaher’s products support critical applications across pharmaceutical development, academic research, clinical laboratories, food and beverage safety, and environmental testing. In life sciences, the company’s instruments and consumables enable genomic sequencing, flow cytometry and microscopy. In diagnostics, its platforms deliver rapid molecular testing and advanced immunoassays. In environmental and applied markets, Danaher’s solutions ensure safe drinking water, efficient industrial processes and accurate product identification.

Under the leadership of President and Chief Executive Officer Rainer Blair, who assumed the role in 2016, Danaher continues to emphasize innovation and operational excellence. The company employs approximately 69,000 people across North America, Europe, Asia-Pacific and Latin America, maintaining research facilities, manufacturing sites and customer support centers around the globe. Danaher’s diversified portfolio and commitment to continuous improvement position it as a leading partner for organizations seeking to advance scientific discovery and improve global health and sustainability.

View Danaher Profile

More Earnings Resources from MarketBeat